Acute pancreatitis is a common digestive disease of which the severity may vary from mild, edematous to severe, necrotizing disease. An improved outcome in the severe form of the disease is based on early identification of disease severity and subsequent focused management of these high-risk patients. However, the ability of clinicians to predict, upon presentation, which patient will have mild or severe acute pancreatitis is not accurate. Prospective systems using clinical criteria have been used to determine severity in patients with acute pancreatitis, such as the Ranson's prognostic signs, Glasgow score, and the acute physiology and chronic health evaluation II score (APACHE II). Their application in clinical practise has been limited by the time delay of at least 48 h to judge all parameters in the former two and by being cumbersome and time-consuming in the latter. Contrast-enhanced computed tomography is presently the most accurate non-invasive single method to evaluate the severity of acute pancreatitis. It cannot, however, be performed to all patients with acute pancreatitis. Therefore, considerable interest has grown in the development of reliable biochemical markers that reflect the severity of acute pancreatitis. In this article we critically appraise current and new severity markers of acute pancreatitis in their ability to distinguish between mild and severe disease and their clinical utility.
INTRODUCTION
Acute pancreatitis is a commonly encountered disease that in the majority of cases is self-limiting with an uneventful recovery and a mortality of less than 2%(1). In about 20 % of the attacks, however, severe acute pancreatitis develops. Despite considerable improvements in the treatment, the mortality remains between 15 and 25 % (2-4). The incidence and aetiology of acute pancreatitis varies considerably in different countries. In about 80 % of the cases acute pancreatitis is caused either by biliary stones or by ethanol abuse (5).
The pathopysiology of acute pancreatitis is still only partly understood. The aetiology of acute pancreatitis can be very variable, but regardless of the etiological factor, premature intra-acinar activation of trypsinogen to trypsin within the pancreas is thought to play a key role as an early triggering event in acinar cell injury (6, 7). Furthermore, due to its unique ability to activate all pancreatic proenzymes, trypsin is thought to be the crucial enzyme causing pancreatic autodigestion (8). Furthermore, it has become increasingly clear that severe acute pancreatitis progresses in two phases. In the first phase, extensive pancreatic inflammation and necrosis are followed by a systemic inflammatory response syndrome that may lead to multiple organ dysfunction syndrome within the first week, without any appar-ent bacterial infection (9) . Unless this process is arrested and reversed by natural defences or therapeutic interventions, the second phase ensues usually after the second week of onset, and is related to the formation of infected pancreatic necrosis or fluid collections with possible progression to overt sepsis, multiple organ dysfunction syndrome and death.
The development of severe acute pancreatitis and the risk of life-threatening complications appear to be multifactorial. Genetically determined predisposing factors causing variable responses to the same biological stimuli, may affect disease severity (10) . High age, comorbidity and a history of continuous medication also influence the overall outcome (11) as well as the initial treatment in the early phase of the disease. This is emphasised in a recent study showing that patients with severe acute pancreatitis admitted to the intensive care unit after a delay of more than 24 h have a four-fold risk of dying (12) . There seems to be therapeutic window within the first 48 h, when specific treatment alternatives may alter the patients' outcome. Good results have been obtained with early management of the patients correctly classified as severe, in intensive care units, with early endoscopic retrograde cholagiopancreatography in gallstone-induced disease, and prophylactic antibiotics (12) (13) (14) . Conversely, reliable exclusion of patients with severe acute pancreatitis helps to avoid unnecessary use of invasive and otherwise costly procedures in mild cases, facilitating optimal use of limited health care resources. The problem in the early phase severity assessment is the lack of accurate predictors. During the past 20 years many attempts have been made to create scoring systems and laboratory markers for early severity assessment of acute pancreatitis, but the methods available are generally considered unsatisfactory (15) .
Besides clinical assessment, amylase and lipase measurements, supported by imaging methods, are the mainstays of the diagnosis of acute pancreatitis. However, the non-specific increases of amylase and lipase are well known and neither correlates with the severity of the acute pancreatitis. The diagnosis of acute pancreatitis is not always straightforward, as shown by the many cases diagnosed only at autopsy (16, 17) . The ability of the clinicians to assess the severity of acute pancreatitis is poor and a significant number of patients with severe disease are misidentified as having mild disease, thus, being under treated with potentially worsened outcome.
Multi-factorial scoring systems, as the Ranson's prognostic signs (18) and the Glasgow score (19, 20) , can be evaluated only 48 h after admission, which is too late for therapeutic decision-making. The acute physiology and chronic health evaluation II score (APACHE II) has the advantage of being evaluable a few hours after admission, and it can be assessed serially. However, it is cumbersome, which limits its use in clinical practice (21) . Contrast-enhanced computed tomography is presently the most accurate non-invasive single method to diagnose and to evaluate the severity of the disease (22, 23) . Magnetic resonance imaging has shown no advantage over contrast-enhanced computed tomography in diagnosing or staging acute pancreatitis (24) . Further, the very long scanning time makes the procedure cumbersome and the availability is often limited. For patients with a clear case of acute pancreatitis, computed tomography imaging is largely unnecessary, but if a patient's clinical presentation is atypical or the enzyme levels are not diagnostic, computed tomography should be used to avoid misdiagnosis of acute pancreatitis. Computed tomography should also be used later during hospitalisation to identify complications (22) . Contrast-enhanced computed tomography is currently considered the best method (23) to identify severe cases. It cannot, however, be performed to all patients with acute pancreatitis due to the risk of renal complications. Therefore, significant interest has grown to develop reliable biochemical markers that reflect the severity of acute pancreatitis in an early phase of the disease. An ideal laboratory assay in the evaluation of a patient with acute pancreatitis should provide an early severity assessment to facilitate the appropriate treatment modalities. Further, it should be applicable in the clinical setting, be rapid, low cost, accurate and available on a 24-hour basis.
Here we review the current severity markers of acute pancreatitis and discuss new markers and their clinical value in evaluating patients with acute pancreatitis. The markers can be subdivided into those indicating activation of inflammation, those correlating with the extent of pancreatic injury, and those measuring activation peptides that reflect the proteolytic insult.
MARKERS OF SEVERITY

MARKERS OF INFLAMMATION
C-reactive protein (CRP)
C-reactive protein (CRP) is a non-specific marker of inflammation. It is synthesized by hepatocytes (25) and is elevated in various inflammatory conditions. The synthesis of CRP is induced by the release of interleukins 1 (IL-1) and interleukin 6 (IL-6). CRP is the most widely used predictor of severity in acute pancreatitis (26, 27) . However, while useful in the follow-up of the disease, there is a 48-to 72-hour delay until peak values are reached, which limits its use for early evaluation of the severity of acute pancreatitis (26) (27) (28) . Multiple cut-off levels to predict severe acute pancreatitis have been used in the literature; presently a level of 150 mg/ml has most often been recommended (29) . In a recent European multicentre study, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) 48 h after admission were 86 %, 61 %, 37 %, 94 %, respectively, and the positive likelihood ratio (PLR) was 2.2 (27) . The advantages of CRP are that it is easy to measure, cheap and widely available.
Cytokines
Proinflammatory cytokines are considered to be important in the pathogenesis of severe acute pancrea-titis. IL-6 is the key mediator for acute phase protein synthesis in the liver (30) . It distinguishes between severe and mild acute pancreatitis with 86 % to 100 % sensitivity and 71 % to 100 % specificity (30, 31) . Peak concentrations of IL-6 are reached 24 to 48 h before those of CRP (32) . A rapid assay for serum concentration of IL-6 is available for the routine use (30) . It is, however, expensive.
Interleukin-8 (IL-8) is also an inflammatory cytokine whose primary target cell is the neutrophil, where it causes degranulation and release of enzymes such as elastase (33) . The kinetics of interleukin-8 (IL-8) is closely similar to IL-6 in acute pancreatitis (30, 31) and correlates also with the disease severity (33) . IL-8 increases even earlier than IL-6 in acute pancreatitis (32) .
Other cytokines have been evaluated as well for the severity assessment of acute pancreatitis. In a recent study, the accuracy of interleukin-10 (IL-10), a cytokine that inhibits the release of proinflammatory cytokines by macrophages, was similar to IL-6 in predicting organ failure in acute pancreatitis. In logistic regression analysis IL-10 showed a better independent prognostic value than IL-6. The combination of IL-10 and serum calcium was significantly better than any single marker or APACHE II score in identifying patients at risk of developing organ failure in acute pancreatitis (34) .
Interleukin-1 (IL-1) is produced during acute and chronic inflammation, and showed no correlation with the severity of acute pancreatitis (35) , whereas the release of tumour necrosis factor alpha (TNF-α ), a macrophage-derived cytokine believed to be important during injury and sepsis (36) , was more strongly elevated in severe than mild acute pancreatitis (31, 35) . However, other studies suggest that measurement of TNF-α is of no clinical value in assessing the severity of acute pancreatitis (37) .
Procalcitonin (PCT)
Procalcitonin (PCT), which is the precursor of calcitonin, is a new serum marker reported to be associated with severe infection and inflammation (38, 39) . It has been proposed to be useful for the detection of bacterial contamination of pancreatic necrosis (40), although contradictionary reports have been presented (41) . In the study by Kylänpää-Bäck et al. the PCT concentrations at 12 h and 24 h after admission were markedly higher in those severe acute pancreatitis patients, who subsequently developed organ failure (42) . A rapid semiquantitative PCT-assay has been developed and is suggested to be valuable in differentiating between severe and mild cases of acute pancreatitis (43) .
Other markers of inflammation
Other markers of immune response evaluated as severity markers in acute pancreatitis include polymorphonuclear elastase and serum amyloid A. In severe acute pancreatitis, neutrophils cumulate in the pancreas, producing elastase that degrades components of the extracellurar matrix (44) . The elastase concen-trations in plasma have been found to be higher in severe than in mild acute pancreatitis (45) , and moreover, neutrophil elastase increases earlier than CRP.
Serum amyloid A is a non-specific marker of inflammation acting as an acute phase reactant. In a recent study by Mayer et al. serum amyloid A predicted severe acute pancreatitis better than CRP during the first 24 h after hospitalisation, having a sensitivity of 67 %, specificity of 70 % and negative predictive value of 89 %, respectively (46) . However, CRP has been shown to predict pancreatic necrosis (proven by computed tomography or surgery) more accurately than serum amyloid A (47, 48) . Although a rapid automated immunoassay has become commercially available for the measurement of polymorphonuclear elastase, have neither polymorphonuclear elastase nor serum amyloid A become widely used as severity markers in the clinical setting.
MARKERS OF PANCREATIC INJURY
Trypsin-related markers
In acute pancreatitis the inflammatory process leads to leakage of pancreatic enzymes into circulation. Trypsinogen-2 has been shown to correlate with the severity of the disease (49, 50) . We recently showed that with a raised cut-off value (2000 µ g/l) the rapid actimPancreatitis ® dipstick test, which can be used as a screening test for acute pancreatitis, can be used for assessment of severity in patients with acute pancreatitis (28) . The result of the dipstick test is available within 5 minutes and requires no laboratory equipment and can be performed by nursing personnel. On admission to hospital the sensitivity and specificity of the dipstick test were 62 % and 87 %, respectively.
A variety of protease inhibitors inactivates trypsin reaching into circulation, of which α 1 -antitrypsin is the quantitatively dominating one. Strongly elevated serum concentrations of trypsin-1-α 1 -antitrypsin and trypsin-2-α 1 -antitrypsin concentrations have been found in patients with acute pancreatitis. Trypsin-2-α 1 -antitrypsin complex levels in serum have been shown to predict severity in acute pancreatitis more accurately than CRP over the initial 12 to 24 h after admission (51) . The assay method of α 1 -antitrypsin is time-consuming, however, and cannot be accepted as a clinical routine method.
In a study by Pezzili et al. (52) serum pancreatic secretory trypsin inhibitor (PSTI) showed to be a better early marker of severity than CRP in acute pancreatitis and in our study (53) urinary PSTI emerged as a potential new marker of severe acute pancreatitis. Though promising, these results need confirmation and development of a more rapid assay in order to make it clinically useful.
Phospholipase A 2 (PLA2)
Of the different phospholipase A 2 (PLA2) isoenzymes, group II PLA2 shows correlation with disease severity in acute pancreatitis (54) . Group II PLA2 concentrations in serum have been shown to be higher in patients with infected pancreatic necrosis than in those with sterile necrosis (55) . Additionally, group II PLA2 correlated with the appearance of systemic inflammatory response syndrome (SIRS) in severe acute pancreatitis (56) . At present, however, the cumbersome assay method prevents its clinical use.
ACTIVATION PEPTIDES
Trypsinogen activation peptide (TAP)
High levels of TAP in urine correlate with the severity of acute pancreatitis (27, 57, 58) . Urinary TAP has showed 24 h after admission a sensitivity of 68 %, specificity of 74 %,and a positive likelihood ratio (PLR) of 2.6, respectively, in distinguishing between severe and mild acute pancreatitis (27) . TAP values in plasma of patients with acute pancreatitis also correlate with the severity of the disease on admission, but the prognostic accuracy declines rapidly, due to the fast elimination from circulation (59) . A limitation of TAP is the enzyme-linked immunosorbent assay (ELISA), which takes several hours to complete and is not widely available. An automated assay method is needed if TAP is to be used in clinical practise.
Other activation peptides
In addition to TAP, phosopholipase A 2 activation peptide (PLAP) and carboxypeptidase B activation peptide (CAPAP) have been evaluated as severity markers of acute pancreatitis (60) (61) (62) . PLAP peak values were seen 12 and 24 h after symptom onset, preceding the increase of IL-6 and CRP (60) . CAPAP discriminates well between severe and mild acute pancreatitis (63, 64) . In the study of Appelros et al. the sensitivity was 92 %, and specificity 89 %, within 72 h from symptom onset (64) . The method available for CAPAP measurement is an inconvenient immunoassay, which limits its clinical utility. Table 1 shows the most promising prognostic markers and combinations of different markers for predicting severe acute pancreatitis. These markers cannot be compared directly with each other, since the patient populations, timing of the sampling and assay methods may be variable.
CONCLUSIONS
In the diagnostic and prognostic algorithm in acute pancreatitis the clinical challenge lies in the timely recognition of patients who eventually develop a severe form of the disease and are likely to benefit from early interventions and intensive care.
We conclude that at present, no single biochemical marker can be considered optimal for making a timely and accurate diagnosis and/or early prediction of severity of acute pancreatitis. Most of the markers, such as the cytokines, must be considered experimental and the assays are not suitable for use in the emergency units on a 24 h basis. The cornerstones in the diagnosis of acute pancreatitis are still amylase and lipase, but wider use of the trypsinogen-2 rapid dipstick test (actimPancreatitis ® ) may be recommended, for screening purposes of acute pancreatitis in patients with acute abdominal pain.
There is emerging evidence that certain biochemical markers may help the clinician in the early identification of severe forms of acute pancreatitis. Urinary TAP can be measured relatively easily and has been adequately validated. Nevertheless, a fully automated assay is required to improve its clinical utility. The urinary trypsinogen-2 dipstick test with the higher cut-off level can be used to detect severe disease, but further studies are needed. Future research should also focus on markers such as PCT that showed promising results as an early screening method to detect severe acute pancreatitis, and the combined use of different markers. It is probable that a panel of different tests is needed to improve the CRP = C-reactive protein, TAP = trypsinogen activation peptide, CAPAP = carboxypeptidase B activation peptide, PCT ® -Q = semiquantitative procalcitonin test, PMN = polymorphonuclear elastase, IL-6 = interleukin-6, IL-10 = interleukin-10, NPV = negative predictive value, PPV = positive predictive value early distinction between mild and severe acute pancreatitis. Which test or combination becomes more widespread in its use will depend on availability, cost and ease of performance.
